- Trials with a EudraCT protocol (29)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
29 result(s) found for: Post hoc analysis.
Displaying page 1 of 2.
EudraCT Number: 2009-017148-15 | Sponsor Protocol Number: CCOX189A2483 | Start Date*: 2010-04-12 |
Sponsor Name:NOVARTIS FARMA | ||
Full Title: A retrospective pharmacogenetic analysis of patients with elevated liver enzymes (Hy s law cases or AST/ALT > 10x ULN) in clinical studies CCOX189A0117, CCOX189A2332, CCOX189A2369, CCOX189A0126,... | ||
Medical condition: patients with elevated liver enzymes (Hy s law cases or AST/ALT > 10x ULN | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-004641-42 | Sponsor Protocol Number: 65371 | Start Date*: 2007-04-23 |
Sponsor Name:Gedeon Richter Plc | ||
Full Title: Single center, exploratoric, open-label study to investigate the precise mechanism of action of Cavinton (vinpocetin) | ||
Medical condition: endothel dysfunction and peripherial circulation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-006041-14 | Sponsor Protocol Number: FINA-007 | Start Date*: 2012-10-26 |
Sponsor Name:MerLion Pharmaceuticals GmbH | ||
Full Title: A Multi-Dose, Double-Blind, Double-Dummy, Active Control, Randomized Clinical (Phase II) Study of Two Dosing Regimens of Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Requiring... | ||
Medical condition: Complicated Urinary Tract Infection and/or Acute Polyonephritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-004905-27 | Sponsor Protocol Number: CBD VP 132/05 | Start Date*: 2008-02-01 |
Sponsor Name:Dstl | ||
Full Title: Pharmacokinetic Interactions between Ciprofloxacin and Chloroquine / Proguanil Prophylaxis | ||
Medical condition: Chloroquine/proguanil is used for malaria chemoprophylaxis in areas where chloroquine-resistant Plasmodium falciparum malaria is prevalent, except in regions of Africa where chloroquine/proguanil i... | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-006183-11 | Sponsor Protocol Number: CA180-287 | Start Date*: 2010-01-22 | |||||||||||
Sponsor Name:UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II | |||||||||||||
Full Title: Multicenter, Open-Label, Single Arm Phase II Clinical Trial of Dasatinib in the Treatment of Systemic Mastocytosis (SM) | |||||||||||||
Medical condition: Systemic mastocytosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-004129-89 | Sponsor Protocol Number: Motor-Neuromod_01, Part I-III | Start Date*: 2005-09-19 |
Sponsor Name:Universitätsklinikum Münster | ||
Full Title: Potentiation of procedural motor learning by pharmacological neuromodulation and brain stimulation | ||
Medical condition: Healthy volunteers Patients in the chronic stage (> 1 year) after stroke | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-000353-26 | Sponsor Protocol Number: SAFE-SSPE | Start Date*: 2021-09-20 |
Sponsor Name:Bern University Hospital | ||
Full Title: Clinical Surveillance vs. Anticoagulation for Low-risk Patients with Isolated Subsegmental Pulmonary Embolism: A Multicenter Randomized Placebo-Controlled Non-Inferiority Trial | ||
Medical condition: Isolated subsegmental pulmonary embolism | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2015-000982-30 | Sponsor Protocol Number: 4993/15 | Start Date*: 2016-08-08 | |||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||
Full Title: Personalized pharmacological treatment of chronic obstructive pulmonary disease based on phenotyping: interventional study | |||||||||||||
Medical condition: Chronic obstructive pulmonary disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001824-43 | Sponsor Protocol Number: DS1040-A-U103 | Start Date*: 2016-02-04 |
Sponsor Name:Daiichi Sankyo, Inc. | ||
Full Title: A Phase 1b/2, multi-center, double-blind (principal investigators and study subjects blinded, sponsor unblinded), placebo-controlled, randomized, single-ascending dose study to assess the safety, p... | ||
Medical condition: DS-1040b is an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa) intended to be used for the treatment of thrombotic diseases including acute ischemic stroke (A... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) FR (Completed) GB (Completed) CZ (Completed) ES (Completed) SK (Completed) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2011-003559-21 | Sponsor Protocol Number: CDEB025A2212 | Start Date*: 2012-02-28 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A Retrospective Pharmacogenetic Analysis of Hepatitis C Patients treated with Alisporivir (DEB025) Alone or in Combination with Peg-IFN2a and/or Ribavirin | |||||||||||||
Medical condition: Hepatitis C and how biomarkers affect the response to treatment of the disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) IT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002511-83 | Sponsor Protocol Number: TTP889-201 | Start Date*: 2005-01-03 | |||||||||||
Sponsor Name:TransTech Pharma | |||||||||||||
Full Title: A Multi-Center, Placebo-Controlled Evaluation of the Safety and Efficacy of Three Weeks Extended VTE Prophylaxis with Daily Oral Doses of TTP889 After One Week of Standard Prophylactic Treatment Fo... | |||||||||||||
Medical condition: Antithrombotic in patients at risk for venous thromboembolism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) CZ (Completed) SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000259-35 | Sponsor Protocol Number: 2020_03 | Start Date*: 2022-04-29 | |||||||||||
Sponsor Name:Centre Hospitalier Universitaire de Lille | |||||||||||||
Full Title: Assessment of the interest of a peri-operative antibiotic strategy applied to patients with asymptomatic bacteriuria undergoing intra-vesical botulinum toxin A injections | |||||||||||||
Medical condition: Overactive bladder (OAB) and/or detrusor overactivity (DO) in multiple sclerosis (MS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002369-17 | Sponsor Protocol Number: 2021-01 | Start Date*: 2021-07-22 |
Sponsor Name:GETAID | ||
Full Title: Management of moderate POstoperative recurrence in Crohn's disease: a randoMizEd contROLled trial, the POMEROL trial. | ||
Medical condition: Crohn's disease patients having an i2 endoscopic postoperative recurrence 6-12 months after ileocolonic anastomosis. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000678-44 | Sponsor Protocol Number: GA1116 | Start Date*: 2012-09-04 |
Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd | ||
Full Title: A single-centre, randomised, four-way crossover study to investigate the measurement of the acid pocket and subsequent gastro-oesophageal reflux episodes using a novel pH/impedance catheter in subj... | ||
Medical condition: A single-centre, randomised, four-way crossover study to investigate the measurement of the acid pocket and subsequent gastro-oesophageal reflux episodes using a novel pH/impedance catheter in subj... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2017-002245-29 | Sponsor Protocol Number: BB2121-MM-001 | Start Date*: 2018-10-02 | ||||||||||||||||
Sponsor Name:Celgene Corporation | ||||||||||||||||||
Full Title: A phase 2, multicenter study to determine the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma | ||||||||||||||||||
Medical condition: Relapsed and Refractory Multiple Myeloma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) BE (Completed) FR (Completed) ES (Ongoing) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-000867-10 | Sponsor Protocol Number: D933QC00001 | Start Date*: 2018-11-02 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Li... | |||||||||||||
Medical condition: Patients with Stage I-III Limited Disease Small-Cell Lung Cancer (LD-SCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003499-37 | Sponsor Protocol Number: DSC/11/2357/44 | Start Date*: 2013-01-20 | |||||||||||
Sponsor Name:ITALFARMACO | |||||||||||||
Full Title: Long-term study evaluating the effect of Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. | |||||||||||||
Medical condition: Chronic myeloproliferative neoplasms (cMPN). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) DE (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001319-36 | Sponsor Protocol Number: FIERCE-21(B-701-U21) | Start Date*: 2017-08-23 | |||||||||||
Sponsor Name:BioClin Therapeutics, Inc. | |||||||||||||
Full Title: A Dose Escalation, Expansion Study of Vofatamab (B 701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects with Locally Advanced or Metastatic Urothelial Cell Carcinoma who have Relapsed After,... | |||||||||||||
Medical condition: Treatment of progressed or refractory metastatic UCC | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002467-27 | Sponsor Protocol Number: 2007 Neuro 12 | Start Date*: 2008-01-24 | |||||||||||||||||||||
Sponsor Name:Salford Royal NHS Foundation Trust | |||||||||||||||||||||||
Full Title: Antidyskinetic Properties of Topiramate: A Double-Blind, Placebo-Controlled Trial in Patients with Parkinson's Disease and Levodopa-Induced Dyskinesias | |||||||||||||||||||||||
Medical condition: Patients with idiopathic Parkinson's disease and levodopa-induced dyskinesias | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-003546-16 | Sponsor Protocol Number: Debio1143-106 | Start Date*: 2019-03-06 |
Sponsor Name:Debiopharm International SA | ||
Full Title: SMARTPLUS-106: Debio 1143 a SMAC Mimetic In Combination With Nivolumab In Patients Failing Prior PD-1/PD-L1 Treatment: A Basket Trial A dose-optimization, exploratory phase Ib/II study to assess... | ||
Medical condition: Solid Tumors | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
